A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
← catalyst calendarNCT07496450 · readout in 162 d
Sponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Prevention
Enrollment
4,050actual
Sites
35
Countries
United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-23 | actual | When the study began enrolling |
| Primary completion | 2027-01-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-28 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Influenza
Interventions
- Biological: mRNA-1018-H5
- Biological: Placebo
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants With Hemagglutination Inhibition (HAI) Titer ≥ 1:40 at Day 43
measured Day 43
Percentage of Participants With Seroconversion at Day 43, as Measured by HAI Assay
measured Day 43
Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)
measured Up to Day 29 (7 days after each injection)
Number of Participants with Unsolicited Adverse Events (AEs)
measured Up to Day 50 (28 days after each injection)
Number of Participants with AEs Leading to Discontinuation, Medically-attended AEs (MAAEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs)
measured Day 1 to Day 205
Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed